

Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT

NCT06693791

Status	RECRUITING
Phase	Phase 2
Sponsor	Anhui Provincial Hospital
Enrollment	34 participants

Key Eligibility Criteria

Inclusion (4)

- Age ≥12 years old, male or female;
- Patients diagnosed with hematological malignancies and undergoing UCBT;
- ECOG score ≤2;
- Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent

Exclusion (13)

- Pregnant or lactating women
- Known allergy to Romiplostim N01;
- A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation;
- A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;
- Chronic active hepatitis B and C;
- ... and 8 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China